Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

FDA grants Krystal Biotech fast track for cancer treatment

Published 2024-02-13, 07:30 a/m
© Reuters.
KRYS
-

PITTSBURGH - Krystal Biotech , Inc. (NASDAQ:KRYS), a commercial-stage biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to their inhaled KB707 treatment for patients with solid tumors with pulmonary metastases that are relapsed or refractory to standard care. This development aims to address the lack of immunotherapy options for many cancers that predominantly metastasize to the lungs.

KB707 is a genetically modified HSV-1 vector that delivers genes for human interleukin-12 (IL-12) and interleukin-2 (IL-2) to the tumor environment, potentially promoting systemic immune-mediated tumor clearance. The FDA also cleared an amendment to the company's Investigational New Drug application in January 2024, allowing the evaluation of inhaled KB707 in a Phase 1 clinical trial for patients with advanced lung tumors.

The trial, known as KYANITE-1, is set to begin in the first half of 2024, with the first patient expected to be dosed during this period. The study is an open-label, multicenter, monotherapy dose escalation and expansion trial.

This is the second Fast Track Designation for KB707; the first was granted in July 2023 for the treatment of locally advanced or metastatic melanoma that is relapsed or refractory to anti-programmed cell death protein-1 therapy.

Krystal Biotech, headquartered in Pittsburgh, Pennsylvania, focuses on genetic medicines for diseases with significant unmet medical needs. Their first commercial product, VYJUVEK®, is the first redosable gene therapy approved by the FDA for dystrophic epidermolysis bullosa.

The information in this article is based on a press release statement from Krystal Biotech, Inc.

InvestingPro Insights

As Krystal Biotech, Inc. (NASDAQ:KRYS) continues to make strides in the biotechnology sector with recent FDA designations, investors are closely monitoring the company's financial health and market performance. According to InvestingPro data, Krystal Biotech holds a market capitalization of $3.27 billion USD, showcasing its substantial size within the biotech industry. Despite not being profitable over the last twelve months, with a P/E ratio (adjusted) of -31.03, the company's strong cash position is reflected in its balance sheet, holding more cash than debt, which provides financial flexibility for ongoing research and development activities.

An InvestingPro Tip highlights that Krystal Biotech's liquid assets exceed its short-term obligations, indicating a robust liquidity position that can support the company through its clinical trials and potential market expansions. Additionally, the company has experienced a significant 3-month price total return of 16.25%, reflecting investor confidence in its growth prospects and recent clinical advancements. Moreover, with 3 analysts having revised their earnings upwards for the upcoming period, there's an optimistic outlook for the company's financial future.

For those considering an investment in Krystal Biotech, it's worth noting that the company does not pay dividends to shareholders, as it reinvests earnings back into its core business operations. To explore more insights and get a deeper analysis of Krystal Biotech, including additional InvestingPro Tips, visit https://www.investing.com/pro/KRYS. There are 9 more tips available on InvestingPro that could provide further guidance on investment decisions. Don't forget to use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.